Comprehensive Appeal Guide: HCPCS J1745 (Infliximab, Excludes Biosimilar)

---

1. Introduction

HCPCS J1745 describes injection, infliximab, excludes biosimilar, 10 mg — the brand-name biologic Remicade administered in a clinical setting. Because J1745 is billed per 10 mg unit, a typical adult infusion requiring 300–500 mg will generate 30–50 units on the claim. This unit-based structure is one of the first things reviewers scrutinize, making clean claim submission and robust documentation essential from day one.

Infliximab is a TNF-alpha inhibitor used across several FDA-approved indications including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Despite its well-established clinical profile, J1745 denials are among the most frequent and highest-dollar biologic denials processed by hospital outpatient departments, infusion suites, and physician offices alike.

Denials happen for many reasons — step therapy failures, biosimilar substitution pressure, authorization lapses, or simple coding errors — and the financial stakes per claim can easily reach $10,000–$25,000 or more. This guide provides a practical, payer-specific roadmap for winning those appeals.

---

2. Common Denial Reasons

Understanding why J1745 gets denied is the foundation of every successful appeal. The seven most common denial categories are:

• No Prior Authorization / Authorization Not Obtained — Infliximab almost universally requires prior authorization. Claims submitted without a valid auth, or after auth expiration, are routinely denied.

• Step Therapy / Fail-First Requirements Not Met — Most payers require documented failure of conventional therapies (e.g., corticosteroids, immunomodulators, MTX) and sometimes one or more TNF-alpha inhibitors before approving J1745.

• Biosimilar Substitution Denial — Because J1745 explicitly excludes biosimilar, payers increasingly require use of an FDA-approved infliximab biosimilar first. A claim for J1745 may be denied with a redirect to a biosimilar HCPCS code (e.g., Q5103, Q5121).

• Diagnosis Not Covered / Medical Necessity Not Established — The submitted ICD-10 diagnosis may not match the payer's covered indications, or the clinical record may lack sufficient documentation of disease severity.

• Units Billed Incorrectly — J1745 is billed per 10 mg. Billing errors (e.g., billing total dose instead of units, or miscalculating weight-based dosing) trigger automatic denials or audits.

• Site of Service Issues — Some payers restrict infliximab infusions to specific sites (e.g., home infusion or outpatient hospital vs. physician office) and deny claims from non-preferred settings.

• Lack of Specialist Involvement / Documentation Gaps — Payers often require that a board-certified specialist (gastroenterologist, rheumatologist, dermatologist) manage the therapy, and that clinical notes reflect ongoing disease assessment.

---

3. Payer-Specific Requirements

Aetna

Medical Policy Criteria
Aetna's clinical policy bulletins for infliximab require documented moderate-to-severe disease, failure of conventional therapy, and specialist oversight. For RA, failure of at least one DMARD is typically required. Aetna has been aggressive about biosimilar-first edits; new starts for infliximab may be redirected to a biosimilar unless the patient has a documented clinical contraindication or prior biosimilar failure.

Required Documentation

• Letter of medical necessity from the treating specialist


• Chart notes demonstrating disease severity scoring (e.g., Harvey-Bradshaw Index, CDAI, DAS28)


• Documented failure or contraindication to step-therapy agents


• Prior auth number on the claim

Key Differences
Aetna is particularly stringent on biosimilar-first for new starts. Patients already stable on Remicade (continuation of therapy) have a stronger argument for J1745 continuity.

Tips

• Reference Aetna's own clinical policy bulletin in the appeal letter


• Emphasize "transition risk" if the patient is currently stable — cite published literature on nocebo effect and anti-drug antibody risk with non-medical switching

---

Anthem / Elevance Health

Medical Policy Criteria
Anthem/Elevance uses commercial and Medicare Advantage medical policies that require clinical diagnosis confirmation, step therapy compliance, and in many markets, mandatory biosimilar utilization for new initiations. Anthem has implemented hard edits in several states requiring biosimilar dispensing.

Required Documentation

• Specialist attestation with diagnosis and severity documentation


• Proof of prior therapy failure (dates, agents, doses, duration, reason for discontinuation)


• Current weight (for weight-based dosing verification)


• Site of service justification if in hospital outpatient setting

Key Differences
Anthem varies significantly by state/Blue plan. Always pull the state-specific policy, not just the national Anthem policy. Some Blue-affiliated plans under Anthem have separate medical policies.

Tips

• For continuation claims, submit with the original authorization documentation alongside the renewal


• Anthem's peer-to-peer review line is often the fastest path to reversal on medical necessity denials — request it within 72 hours of denial

---

Blue Cross Blue Shield (Independent Plans)

Medical Policy Criteria
Independent BCBS plans (e.g., BCBS of Texas, Florida, Michigan) each maintain their own medical policies. Most follow a common framework requiring step therapy, but the specific agents and duration requirements vary. Many BCBS plans now have specialty pharmacy carve-outs affecting J1745 buy-and-bill models.

Required Documentation

• Plan-specific prior authorization approval


• Clinical notes from a board-certified specialist


• Documented step therapy compliance per that plan's specific requirements


• NDC number on the claim in addition to J1745 for some plans

Key Differences
The BCBS patchwork means a policy that works in one state may not apply in another. Always verify the local plan's policy number and criteria. Some plans (e.g., BCBS Federal Employee Program) have distinct and sometimes more favorable policies.

Tips

• Call the provider line before filing the appeal to confirm which clinical policy applies


• Include the NDC for the specific infliximab product on the claim — this can prevent "biosimilar confusion" denials


• FEP members often have more favorable continuation-of-therapy provisions

---

Cigna

Medical Policy Criteria
Cigna's coverage criteria for J1745 follow their Medical Coverage Policies requiring FDA-approved indication, specialist management, step therapy documentation, and in many cases biosimilar-first for new initiations. Cigna has implemented quantity limits that correspond to standard weight-based dosing intervals.

Required Documentation

• PA approval documentation


• Clinical notes supporting moderate-to-severe classification


• Response/monitoring documentation for continuation authorizations


• Infusion administration records

Key Differences
Cigna is particularly focused on clinical response documentation for renewals. A patient continuing on J1745 must show objective improvement or stability — subjective "doing well" notes are insufficient.

Tips

• For renewal appeals, submit objective disease scoring at baseline AND current visit


• Cigna's medical director review process responds well to detailed peer-reviewed literature on biosimilar switching risks


• If denied for biosimilar-first, document any allergy, intolerance, or prior biosimilar trial specifically

---

Humana

Medical Policy Criteria
Humana (commercial and Medicare Advantage) uses clinical criteria aligned with FDA labeling and requires step therapy for most inflammatory conditions. Humana MA plans are especially important to understand separately from commercial, as formulary placement and step therapy requirements can differ substantially.

Required Documentation

• Completed prior authorization with all clinical questions answered


• Specialist consultation notes


• Lab work supporting diagnosis (e.g., CRP, ESR, RF, anti-CCP for RA; endoscopy reports for IBD)


• For MA: Medicare-compliant documentation standards apply

Key Differences
Humana Medicare Advantage plans follow Medicare coverage guidelines as a floor but may add step therapy requirements on top. The Part B biologic billing rules (J1745 under medical benefit) apply, but Humana MA may impose additional formulary management.

Tips

• Always verify whether the patient's Humana plan is commercial or Medicare Advantage — the appeal pathways and standards differ


• Submit lab reports and imaging/endoscopy findings to strengthen medical necessity — Humana reviewers respond well to objective evidence


• Request expedited review if the patient is currently mid-treatment

---

Medicare Traditional (Parts A & B)

Medical Policy Criteria
Under Medicare Part B, J1745 is covered as a physician-administered drug when medically necessary. Medicare does not impose biosimilar-step therapy in the same way commercial payers do, but Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs) govern medical necessity. Medicare requires the drug be administered incident-to or by/under direct supervision of a physician.

Required Documentation

• Proper ICD-10 diagnosis code linked to J1745


• Correct units (per 10 mg) and NDC number


• Documentation of medical necessity in the medical record


• Incident-to requirements met if billed by a physician practice


• HCPCS modifier if applicable (e.g., -JW for discarded drug, -JZ for no drug discarded)

Key Differences
Medicare does not require prior authorization for most Part B drug claims under Traditional Medicare, but does conduct post-payment audits via RAC, MAC, and OIG. Documentation integrity is paramount. The -JW/-JZ modifier requirement (effective January 2023) is strictly enforced.

Tips

• Audit your units calculation: dose (mg) ÷ 10 = units to bill. Document the exact mg administered and any waste


• Ensure the treating physician's NPI is on the claim and that supervision requirements are met


• For Medicare Advantage plans marketed as "Medicare," apply the commercial payer rules above — Traditional Medicare rules do not automatically apply

---

Molina Healthcare

Medical Policy Criteria
Molina primarily serves Medicaid and Marketplace (ACA) populations. State Medicaid policies govern coverage, and Molina must follow state-specific Medicaid Drug Utilization Review (DUR) requirements. Many state Medicaid programs have preferred drug lists and mandatory biosimilar substitution policies that directly impact J1745 claims.

Required Documentation

• State Medicaid PA approval


• Clinical notes confirming FDA-approved indication


• Failure of preferred/lower-cost agents per state PDL


• For Marketplace plans: standard commercial criteria apply

Key Differences
Molina's policies are highly state-dependent. A J1745 appeal in Texas Medicaid (Molina) may require entirely different documentation than in Ohio or Washington. Always look up the state Medicaid fee schedule and preferred drug list before appealing.

Tips

• Contact your state's Medicaid pharmacy director office if Molina denies and state policy is ambiguous


• Frame appeals around the state Medicaid clinical criteria, not commercial criteria


• "Access to medically necessary care" arguments carry weight in Medicaid appeals and can be escalated to the state ombudsman

---

UnitedHealthcare

Medical Policy Criteria
UHC uses its commercial Medical Policy library and has implemented mandatory biosimilar-first edits for new infliximab initiations in most commercial lines. UHC also has a specialty pharmacy program (Optum Rx) that may direct infliximab dispensing away from buy-and-bill, creating site-of-service and billing conflicts.

Required Documentation

• UHC PA approval number on the claim


• Clinical criteria documentation per UHC's applicable policy


• Step therapy compliance documentation


• For continuation: documented clinical response/stability

Key Differences
UHC's integration with Optum creates specialty pharmacy channel requirements that can result in J1745 denials when the drug is purchased through buy-and-bill rather than Optum specialty pharmacy. This is one of the most common and frustrating UHC-specific denial patterns.

Tips

• Verify the dispensing channel requirement before ordering the drug — this prevents the most common UHC J1745 denial


• If denied due to specialty pharmacy channel: appeal on patient safety/continuity grounds and request a site-of-care exception


• UHC's Provider Advocate line can be highly effective for complex biologic appeals — use it before submitting the written appeal when possible

---

4. Required Documentation Checklist

Regardless of payer, every J1745 appeal should include:

• [ ] Complete medical records — specialist notes documenting diagnosis, severity, and treatment history (minimum 3–6 months)


• [ ] Objective disease severity scoring — validated tools appropriate to the condition (CDAI, PUCAI, DAS28, PASI, BASDAI, etc.)


• [ ] Step therapy documentation — dates, drugs, doses, duration, and documented reason for failure/discontinuation of each prior agent


• [ ] Letter of medical necessity — signed by the treating specialist, specific to infliximab (J1745), with clinical rationale


• [ ] Prior authorization approval documentation (if applicable — copy of the approval with auth number)


• [ ] Infusion administration records — confirming dose administered, date, and supervising provider


• [ ] NDC number for infliximab — confirming the non-biosimilar product was dispensed


• [ ] Claim copy (CMS-1500 or UB-04) — showing J1745, correct units, diagnosis codes, and provider information


• [ ] Explanation of Benefits (EOB) or Remittance Advice — showing the specific denial reason code and remark code


• [ ] Published clinical literature (for biosimilar-switching or complex medical necessity arguments)


• [ ] Patient history of biosimilar failure or contraindication (if biosimilar-first denial)

---

5. Sample Appeal Arguments

Argument 1: Established Clinical Response — Continuation of Therapy

> "The patient has been receiving infliximab (J1745) for [X months/years] with documented clinical remission as evidenced by [objective measure]. Switching to a biosimilar or alternative agent in a clinically stable patient creates unnecessary risk of disease relapse, immunogenicity, and nocebo response without therapeutic benefit. Interrupting effective therapy is not medically appropriate and is inconsistent with evidence-based treatment guidelines (ACR, ACG, AAD)."

Argument 2: Step Therapy Fully Satisfied

> "Prior to initiating infliximab (J1745), the patient completed a documented trial of [Agent A, dates, dose, outcome] and [Agent B, dates, dose, outcome], both of which were discontinued due to [inadequate response/intolerance/contraindication]. All step therapy requirements outlined in the payer's medical policy have been satisfied. Continued denial constitutes a barrier to medically necessary care."

Argument 3: Biosimilar Contraindication / Prior Biosimilar Failure

> "The plan's biosimilar-first requirement is not clinically appropriate for this patient because [the patient previously failed biosimilar X / the patient has a documented allergy or intolerance / the treating physician has determined that non-medical switching poses unacceptable clinical risk]. HCPCS J1745 describes injection, infliximab, excludes biosimilar, 10 mg — the specific product medically indicated for this patient."

Argument 4: Units and Medical Necessity Are Clinically Supported

> "The claim was submitted for [X] units of J1745 (infliximab, excludes biosimilar, 10 mg per unit), reflecting a total dose of [X mg] calculated at [X mg/kg] for a patient weighing [X kg]. This dose is consistent with FDA-approved labeling for [indication], current clinical guidelines, and the patient's documented response history. The units billed are accurate and medically necessary."

---

6. Filing Deadlines

| Payer Type | Typical Appeal Deadline |
|---|---|
| Commercial (Aetna, Anthem, Cigna, UHC, BCBS, Humana) | 180 days from date of denial EOB (some plans allow up to 1 year) |
| Medicare Traditional | 120 days from date of Medicare Summary Notice / Remittance |
| Medicare Advantage | 60 days from date of denial notice |
| Medicaid (Molina and state plans) | Varies by state — commonly 30–90